{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:03:58Z","timestamp":1772089438689,"version":"3.50.1"},"reference-count":47,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This research aimed to establish a population pharmacokinetic (PPK) model for busulfan (Bu) in Chinese pediatric patients with thalassemia major. We analyzed pharmacokinetic (PK) parameter variability and explored potential covariates affecting Bu disposition using patient data. These findings are intended to support the optimization and personalization of Bu dosage regimens for children with thalassemia major.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Concentration-time samples were collected retrospectively from 62 pediatric patients with tha-lassemia major. These patients had previously received intravenous Bu as a preparatory regimen for al-logeneic hematopoietic stem cell transplantation (allo-HSCT). A PPK model of Bu was developed through nonlinear mixed-effects modeling. This modeling process, conducted using NONMEM software, concur-rently involved data analysis and examination of the effect of covariates on Bu pharmacokinetics. For validation purposes, the resulting model was evaluated against an external dataset consisting of 20 indi-viduals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The pharmacokinetic results were optimally analyzed using a model that incorporated a one-compartment model with first-order elimination. Body surface area (BSA) was subsequently identified as the most significant factor influencing both Bu clearance (CL) and volume of distribution (V). Diagnostic evaluations, encompassing goodness-of-fit plots, normalized prediction distribution errors, and visual pre-dictive checks, confirmed the satisfactory fit and predictability of the final PPK model. Moreover, predic-tion-based diagnostic indices (MDPE%, 15.75; MAPE%, 22.26; F20%, 45.71; and F30%, 58.57) from external validation showed that no significant bias was detected when comparing the model's predicted concentrations against the observed data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present study developed the first PPK model characterizing the pharmacokinetics of Bu specifically in children with thalassemia major. This study's final PPK model demonstrated that BSA was the key predictive covariate for CL and V.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892002402673251003055700","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:04:41Z","timestamp":1760961881000},"page":"618-627","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Population Pharmacokinetics Model of Busulfan in Pediatric Patients with Thalassemia Major"],"prefix":"10.2174","volume":"26","author":[{"given":"Fangyuan","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zebin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiru","family":"Su","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shenzhen Children's Hospital, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijian","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, 518000, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"272","volume":"105","author":"Baird D.C.","year":"2022","unstructured":"Baird D.C.; Batten S.H.; Sparks S.K.; Alpha- and Beta-Thalassemia: Rapid evidence review. Am Fam Physician  2022,105(3),272-280","journal-title":"Am Fam Physician"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.4314\/ejhs.v32i6.18","volume":"32","author":"Sonkawade N.D.","year":"2022","unstructured":"Sonkawade N.D.; Kinikar A.A.; Kulkarni R.K.; Dawre R.M.; Valvi C.T.; Kamath P.A.; Screening of extended family members of Thalassemia major children as a Thalassemia preventive strategy. Ethiop J Health Sci  2022,32(6),1203-1210","journal-title":"Ethiop J Health Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3109\/03630260903211698","volume":"33","author":"Li C.G.","year":"2009","unstructured":"Li C.G.; Li C.F.; Li Q.; Li M.; Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province. Hemoglobin  2009,33(5),296-303","journal-title":"Hemoglobin"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41598-017-00967-2","volume":"7","author":"Lai K.","year":"2017","unstructured":"Lai K.; Huang G.; Su L.; He Y.; The prevalence of thalassemia in mainland China: Evidence from epidemiological surveys. Sci Rep  2017,7(1),920","journal-title":"Sci Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ped4.12154","volume":"4","author":"Xu X.","year":"2020","unstructured":"Xu X.; Wu X.; Epidemiology and treatment of beta Thalassemia major in China. Pediatr Investig  2020,4(1),43-47","journal-title":"Pediatr Investig"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1038\/s41409-021-01461-0","volume":"56","author":"Oikonomopoulou C.","year":"2021","unstructured":"Oikonomopoulou C.; Goussetis E.; HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe. Bone Marrow Transplant  2021,56(12),2882-2888","journal-title":"Bone Marrow Transplant"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1177\/0091270010382915","volume":"51","author":"Abbasi N.","year":"2011","unstructured":"Abbasi N.; Vadnais B.; Knutson J.A.; Blough D.K.; Kelly E.J.; O\u2019Donnell P.V.; Deeg H.J.; Pawlikowski M.A.; Ho R.J.Y.; McCune J.S.; Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol  2011,51(10),1429-1438","journal-title":"J Clin Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","volume":"22","author":"Palmer J.","year":"2016","unstructured":"Palmer J.; McCune J.S.; Perales M.A.; Marks D.; Bubalo J.; Mohty M.; Wingard J.R.; Paci A.; Hassan M.; Bredeson C.; Pidala J.; Shah N.; Shaughnessy P.; Majhail N.; Schriber J.; Savani B.N.; Carpenter P.A.; Personalizing busulfan-based conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant  2016,22(11),1915-1925","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e31969","DOI":"10.1002\/pbc.31969","volume":"e31969","author":"He Z.","year":"2025","unstructured":"He Z.; Wang Y.; Zhu H.; Chen Y.; Ye C.; Ou J.; Junyan ; Yu, X.; Population pharmacokinetics of busulfan in pediatric patients: Optimization of a four\u2010times\u2010daily dosing regimen based on EBMT recommendations. Pediatr Blood Cancer  2025,e31969,e31969","journal-title":"Pediatr Blood Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","volume":"33","author":"Nguyen L.","year":"2004","unstructured":"Nguyen L.; Fuller D.; Lennon S.; Leger F.; Puozzo C.I.V.; busulfan in pediatrics: A novel dosing to improve safety\/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant  2004,33(10),979-987","journal-title":"Bone Marrow Transplant"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/pharmaceutics16010013","volume":"16","author":"Schreib K.M.","year":"2023","unstructured":"Schreib K.M.; Br\u00e4m D.S.; Zeilhofer U.B.; M\u00fcller D.; G\u00fcng\u00f6r T.; Kr\u00e4mer S.D.; Hauri-Hohl M.M.; Population pharmacokinetic modeling for twice-daily intravenous busulfan in a large cohort of pediatric patients undergoing hematopoietic stem cell transplantation\u2014A 10-year single-center experience. Pharmaceutics  2023,16(1),13","journal-title":"Pharmaceutics"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","volume":"19","author":"Savic R.M.","year":"2013","unstructured":"Savic R.M.; Cowan M.J.; Dvorak C.C.; Pai S.Y.; Pereira L.; Bartelink I.H.; Boelens J.J.; Bredius R.G.M.; Wynn R.F.; Cuvelier G.D.E.; Shaw P.J.; Slatter M.A.; Long-Boyle J.; Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant  2013,19(11),1608-1614","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/pharmaceutics15071859","volume":"15","author":"Del Valle-Moreno P.","year":"2023","unstructured":"Del Valle-Moreno P.; Suarez-Casillas P.; Mej\u00edas-Trueba M.; Ciudad-Guti\u00e9rrez P.; Guisado-Gil A.; Gil-Navarro M.; Herrera-Hidalgo L.; Model-informed precision dosing software tools for dosage regimen individualization: A scoping review. Pharmaceutics  2023,15(7),1859","journal-title":"Pharmaceutics"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/pharmaceutics14030647","volume":"14","author":"Neroutsos E.","year":"2022","unstructured":"Neroutsos E.; Nalda-Molina R.; Paisiou A.; Zisaki K.; Goussetis E.; Spyridonidis A.; Kitra V.; Grafakos S.; Valsami G.; Dokoumetzidis A.; Development of a population pharmacokinetic model of busulfan in children and evaluation of different sampling schedules for precision dosing. Pharmaceutics  2022,14(3),647","journal-title":"Pharmaceutics"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jtct.2025.07.008","volume":"31","author":"Bartelink I.H.","year":"2025","unstructured":"Bartelink I.H.; Lalmohamed A.; Bognar T.; Nur E.; Boelens J.J.; Optimizing allogeneic hematopoietic cell transplantation outcomes through busulfan PK\/PD. Transplant Cell Ther  2025,31(8),477-479","journal-title":"Transplant Cell Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/FTD.0b013e31826051bb","volume":"34","author":"Bartelink I.H.","year":"2012","unstructured":"Bartelink I.H.; van Kesteren C.; Boelens J.J.; Egberts T.C.G.; Bierings M.B.; Cuvelier G.D.E.; Wynn R.F.; Slatter M.A.; Chiesa R.; Danhof M.; Knibbe C.A.J.; Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit  2012,34(5),574-583","journal-title":"Ther Drug Monit"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","volume":"17","author":"Trame M.N.","year":"2011","unstructured":"Trame M.N.; Bergstrand M.; Karlsson M.O.; Boos J.; Hempel G.; Population pharmacokinetics of busulfan in children: Increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res  2011,17(21),6867-6877","journal-title":"Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/sj.bmt.1703207","volume":"28","author":"Bleyzac N.","year":"2001","unstructured":"Bleyzac N.; Souillet G.; Magron P.; Janoly A.; Martin P.; Bertrand Y.; Galambrun C.; Dai Q.; Maire P.; Jelliffe R.W.; Aulagner G.; Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant  2001,28(8),743-751","journal-title":"Bone Marrow Transplant"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/bmt.2008.437","volume":"44","author":"Tse W.T.","year":"2009","unstructured":"Tse W.T.; Duerst R.; Schneiderman J.; Chaudhury S.; Jacobsohn D.; Kletzel M.; Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant  2009,44(3),145-156","journal-title":"Bone Marrow Transplant"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.2217\/pgs.15.98","volume":"16","author":"Choi B.","year":"2015","unstructured":"Choi B.; Kim M.G.; Han N.; Kim T.; Ji E.; Park S.; Kim I.W.; Oh J.M.; Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. Pharmacogenomics  2015,16(14),1585-1594","journal-title":"Pharmacogenomics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.31547\/bct-2021-019","volume":"5","author":"Salvaris R.","year":"2022","unstructured":"Salvaris R.; Salman S.; O\u2019Halloran S.; Joyce D.; Mathew N.; Cooney J.; Wright M.; Cannell P.; Purtill D.; Evaluating the efficacy, toxicity and pharmacokinetic profile of oral busulfan in allogeneic stem cell transplant patients. Blood Cell Ther  2022,5(2),61-68","journal-title":"Blood Cell Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"106416","DOI":"10.1016\/j.ejps.2023.106416","volume":"186","author":"Yang Y.","year":"2023","unstructured":"Yang Y.; Wang C.; Chen Y.; Wang X.; Jiao Z.; Wang Z.; External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur J Pharm Sci  2023,186,106416","journal-title":"Eur J Pharm Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jpba.2015.12.024","volume":"120","author":"Nadella T.R.","year":"2016","unstructured":"Nadella T.R.; Suryadevara V.; Lankapalli S.R.; Mandava V.B.R.; Bandarupalli D.; LC\u2013MS\/MS method development for quantification of busulfan in human plasma and its application in pharmacokinetic study. J Pharm Biomed Anal  2016,120,168-174","journal-title":"J Pharm Biomed Anal"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cca.2018.01.020","volume":"479","author":"Xiao Y.","year":"2018","unstructured":"Xiao Y.; Li X.; Fu X.; A rapid and simple LC\u2013MS\/MS method for personalized busulfan dosing in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Clin Chim Acta  2018,479,190-195","journal-title":"Clin Chim Acta"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5414\/CP204550","volume":"62","author":"Liu M.","year":"2024","unstructured":"Liu M.; Qin J.; Chu X.; Chen N.; Jie Q.; Zheng S.; Population pharmacokinetic study and application of ticagrelor and AR-C124910XX after percutaneous coronary intervention in Chinese patients with acute coronary syndrome Int J Clin Pharmacol Ther  2024,62(9),412-422","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2147\/DDDT.S303497","volume":"15","author":"Wang X.","year":"2021","unstructured":"Wang X.; Wang Y.; Yao F.; Chen S.; Hou Y.; Zheng Z.; Luo J.; Qiu B.; Li Z.; Wang Y.; Wu Z.; Lan J.; Chen C.; Pharmacokinetics of Linezolid dose adjustment for creatinine clearance in critically ill patients: A multicenter, prospective, open-label, observational study. Drug Des Devel Ther  2021,15,2129-2141","journal-title":"Drug Des Devel Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00228-024-03641-5","volume":"80","author":"Cai R.","year":"2024","unstructured":"Cai R.; Zhang L.; Wu T.; Huang Y.; Lu J.; Huang T.; Wu Y.; Wu D.; Qi J.; Niu L.; Xiao Y.; Chen X.; Liu Y.; Luo Y.; Liu T.; Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation. Eur J Clin Pharmacol  2024,80(5),685-696","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2023-11-2","volume":"13","author":"Grassedonio E.","year":"2024","unstructured":"Grassedonio E.; Incorvaia L.; Guarneri M.; Guagnini F.; Midiri M.; Prevention of post-contrast kidney injury in patients with cancer. Drugs Context  2024,13,1-10","journal-title":"Drugs Context"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"Zhao C.Y.","year":"2016","unstructured":"Zhao C.Y.; Jiao Z.; Mao J.J.; Qiu X.Y.; External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol  2016,81(5),891-907","journal-title":"Br J Clin Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41409-021-01545-x","volume":"57","author":"Shao D.","year":"2022","unstructured":"Shao D.; Li J.; Hu T.; Zhang Z.; Zhang ; li J.; Cao J.; Feng S.; Tang R.; Zhong D.; Song Z.; Yue M.; Hu M.; Xuan L.; Zhai M.; Zhang H.; Wang X.; Shi X.; Liu R.; \nClinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring. Bone Marrow Transplant  2022,57(3),473-478","journal-title":"Bone Marrow Transplant"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e13696","DOI":"10.1111\/petr.13696","volume":"24","author":"Kishimoto K.","year":"2020","unstructured":"Kishimoto K.; Hasegawa D.; Irie K.; Okada A.; Nakamura S.; Tamura A.; Yamamoto N.; Kozaki A.; Saito A.; Ishida T.; Fukushima S.; Kosaka Y.; Pharmacokinetic analysis for model\u2010supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients. Pediatr Transplant  2020,24(4),e13696","journal-title":"Pediatr Transplant"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2010-01-265405","volume":"115","author":"Gaziev J.","year":"2010","unstructured":"Gaziev J.; Nguyen L.; Puozzo C.; Mozzi A.F.; Casella M.; Perrone Donnorso M.; Gravina P.; Sodani P.; Marziali M.; Isgr\u00f2 A.; Simone M.D.; Andreani M.; Formosa A.; Testi M.; Federici G.; Bernardini S.; Lucarelli G.; Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood  2010,115(22),4597-4604","journal-title":"Blood"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13318-017-0431-0","volume":"43","author":"Faraci M.","year":"2018","unstructured":"Faraci M.; Tinelli C.; Lanino E.; Giardino S.; Leoni M.; Ferretti M.; Castagnola E.; Broglia M.; De Silvestri A.; Di Martino D.; Bartoli A.; Monitoring of busulphan concentrations in children undergone hematopoietic stem cell transplantation: Unicentric experience over 10 years. Eur J Drug Metab Pharmacokinet  2018,43(2),173-181","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40262-023-01275-x","volume":"62","author":"Takahashi T.","year":"2023","unstructured":"Takahashi T.; Jaber M.M.; Brown S.J.; Al-Kofahi M.; Population pharmacokinetic model of intravenous busulfan in hematopoietic cell transplantation: Systematic review and comparative simulations. Clin Pharmacokinet  2023,62(7),955-968","journal-title":"Clin Pharmacokinet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.bmt.1701814","volume":"24","author":"Poonkuzhali B.","year":"1999","unstructured":"Poonkuzhali B.; Srivastava A.; Quernin M.H.; Dennison D.; Aigrain E.J.; Kanagasabapathy A.S.; Krishnamoorthy R.; Chandy M.; Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant  1999,24(1),5-11","journal-title":"Bone Marrow Transplant"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/petr.12430","volume":"19","author":"G\u00fcrlek G\u00f6k\u00e7ebay D.","year":"2015","unstructured":"G\u00fcrlek G\u00f6k\u00e7ebay D.; Azik F.; Ozbek N.; Isik P.; Avci Z.; Tavil B.; Kara A.; Tunc B.; Clinical comparison of weight\u2010 and age\u2010based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. Pediatr Transplant  2015,19(3),307-315","journal-title":"Pediatr Transplant"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/PGPM.S289834","volume":"14","author":"Yuan J.","year":"2021","unstructured":"Yuan J.; Sun N.; Feng X.; He H.; Mei D.; Zhu G.; Zhao L.; Optimization of busulfan dosing regimen in pediatric patients using a population pharmacokinetic model incorporating GST mutations. Pharm Genomics Pers Med  2021,14,253-268","journal-title":"Pharm Genomics Pers Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","volume":"20","author":"McCune J.S.","year":"2014","unstructured":"McCune J.S.; Bemer M.J.; Barrett J.S.; Scott Baker K.; Gamis A.S.; Holford N.H.G.; Busulfan in infant to adult hematopoietic cell transplant recipients: A population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res  2014,20(3),754-763","journal-title":"Clin Cancer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1701001","volume":"20","author":"Pawlowska A.B.","year":"1997","unstructured":"Pawlowska A.B.; Blazar B.R.; Angelucci E.; Baronciani D.; Shu X.O.; Bostrom B.; Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant  1997,20(11),915-920","journal-title":"Bone Marrow Transplant"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cpt.3748","volume":"118","author":"Mahomedradja R.F.","year":"2025","unstructured":"Mahomedradja R.F.; Bogn\u00e0r T.; van Schie K.E.; Kuipers I.T.; de Witte M.A.; Kuball J.H.E.; Nur E.; Wilhelm B.J.; Heerma van] ] Voss, M.R.; Franken, L.; Lalmohamed, A.; Swart, E.N.L.; de Leeuw, D.C.; Bartelink, I.H. Model\u2010informed precision dosing of busulfan for children and adults undergoing allogeneic hematopoietic stem cell transplantation: A critical evaluation of current PK models and dose recommendations. Clin Pharmacol Ther  2025,118(3),723-734","journal-title":"Clin Pharmacol Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/FTD.0000000000001225","volume":"46","author":"Puangpetch A.","year":"2024","unstructured":"Puangpetch A.; Thomas F.; Anurathapan U.; Pakakasama S.; Hongeng S.; Rachanakul J.; Prommas S.; Nuntharadthanaphong N.; Chatelut \u00c9.; Sukasem C.; Le Louedec F.; Model-informed precision dosing of intravenous busulfan in Thai pediatrics undergoing hematopoietic stem cell transplantation. Ther Drug Monit  2024,46(6),778-785","journal-title":"Ther Drug Monit"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/bcpt.13185","volume":"124","author":"Kim M.G.","year":"2019","unstructured":"Kim M.G.; Kwak A.; Choi B.; Ji E.; Oh J.M.; Kim K.; Effect of glutathione S\u2010transferase genetic polymorphisms on busulfan pharmacokinetics and veno\u2010occlusive disease in hematopoietic stem cell transplantation: A meta\u2010analysis. Basic Clin Pharmacol Toxicol  2019,124(6),691-703","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=43","first-page":"5509","volume":"57","author":"Gibbs J.P.","year":"1997","unstructured":"Gibbs J.P.; Murray G.; Risler L.; Chien J.Y.; Dev R.; Slattery J.T.; Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res  1997,57(24),5509-5516","journal-title":"Cancer Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/bmt.2015.321","volume":"51","author":"Ansari M.","year":"2016","unstructured":"Ansari M.; Huezo-Diaz P.; Rezgui M.A.; Marktel S.; Duval M.; Bittencourt H.; Cappelli B.; Krajinovic M.; Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in Thalassemia pediatric patients. Bone Marrow Transplant  2016,51(3),377-383","journal-title":"Bone Marrow Transplant"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/bcp.13566","volume":"84","author":"Nava T.","year":"2018","unstructured":"Nava T.; Kassir N.; Rezgui M.A.; Uppugunduri C.R.S.; Huezo-Diaz Curtis P.; Duval M.; Th\u00e9oret Y.; Daudt L.E.; Litalien C.; Ansari M.; Krajinovic M.; Bittencourt H.; Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. Br J Clin Pharmacol  2018,84(7),1494-1504","journal-title":"Br J Clin Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ped.13859","volume":"61","author":"Nishikawa T.","year":"2019","unstructured":"Nishikawa T.; Yamaguchi H.; Ikawa K.; Nakayama K.; Higashi E.; Miyahara E.; Abematsu T.; Nakagawa S.; Kodama Y.; Tanabe T.; Shigemi A.; Shinkoda Y.; Okamoto Y.; Takeda Y.; Kawano Y.; Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. Pediatr Int  2019,61(6),558-565","journal-title":"Pediatr Int"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","volume":"37","author":"Long-Boyle J.R.","year":"2015","unstructured":"Long-Boyle J.R.; Savic R.; Yan S.; Bartelink I.; Musick L.; French D.; Law J.; Horn B.; Cowan M.J.; Dvorak C.C.; Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: A model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit  2015,37(2),236-245","journal-title":"Ther Drug Monit"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002402673251003055700","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/246092\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002402673251003055700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:04:04Z","timestamp":1772085844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/246092\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002402673251003055700","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}